Market research
4598.TSE Delta-Fly Pharma, Inc
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.7
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- JP3549370009
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.7
About
About Delta-Fly Pharma, Inc
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase II/III clinical trials for the treatment of solid cancer; DFP-11207, which in phase I/II clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, to treat gastric/ovarian cancer. The company was incorporated in 2010 and is headquartered in Tokushima, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4598.TSE discussion.
5 years, 5 months ago
Delta-Fly Pharma, Inc is currently in a long term uptrend where the price is trading 6.6% above its 200 day moving average.
From a valuation standpoint, the stock is 59.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 28.6.
Its net income has increased by 38.5% to $-308M since the same quarter in the previous year.
Based on the above factors, Delta-Fly Pharma, Inc gets an overall score of 3/5.